Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning tablets for coronary microvascular disease
ChiCTR2400088473Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Guanxinning in Coronary Small Vessel Disease (CMD), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Myocardial blood flow reserve, Myocardial perfusion reserve index and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
Guanxinning
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2400088473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088473.